Achilles Therapeutics Plc (ACHL)

$1.48 +0.01 (0.68%)
Market Cap 60.83M
Revenue (ttm) 0.00
Net Income (ttm) -69.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,204,100
Avg Vol 1,452,728
Day's Range N/A - N/A
Shares Out 41.10M
Stochastic %K 77%
Beta 1.25
Analysts Sell
Price Target $3.25
DrevanTheStillblade
DrevanTheStillblade Oct. 19 at 4:23 PM
Watch VRME possible super run incoming VRME has a rare “floor + optional upside” setup. Strong cash reserves, improving cash flow, tight structure and a golden cross brewing. When volume steps in, this could stretch beyond typical penny stock ranges. $GLMD $ATHE $ACHL $CRVS
1 · Reply
AttractDontChase
AttractDontChase Sep. 28 at 6:11 PM
IVDA is the sleeper AI + drone play people will pretend they knew about later. With a tiny float and commercial-ready robotics, it could re-rate hard off any government, defense, or safety contract. Bottomed. Unloved. Loaded. $UBX $QH $SGH $ACHL $VYNE
0 · Reply
TradeHuntFish
TradeHuntFish Sep. 24 at 11:15 AM
XPON - The lithium wave is real XPON is tied directly to it. Energy storage, home power, marine, RV all real-world growth verticals. Float is small. Chart is coiled. The next PR or volume burst could launch it. $NLST $SNSE $ACHL $BTTX $GLSI
0 · Reply
rastytwits
rastytwits Mar. 27 at 4:25 PM
$ACHL now that it’s delisted from Nasdaq, how do I sell my shares? Missed the delisting notice.
1 · Reply
Laynester
Laynester Mar. 18 at 2:53 PM
$ACHL Seeing a see of green on $ACHL
0 · Reply
BuyLowSellHigh88
BuyLowSellHigh88 Mar. 14 at 5:46 PM
$ACHL Reasons to Favor TNXP 1. Broad Pipeline: TNXP has a more diversified portfolio targeting multiple conditions, which reduces reliance on a single therapy. 2. Regulatory Progress: TNXP’s lead candidate (TNX-102 SL) is closer to commercialization, with an FDA PDUFA date set for August 2025. 3. Strategic Partnerships: Strong collaborations with Bilthoven Biologicals and X-Chem, Inc. enhance its research capabilities. Key Considerations • Risk: ACHL is riskier due to its narrower focus and recent decision to discontinue key trials, signaling challenges in its pipeline. • Diversification: TNXP’s broader pipeline and advanced regulatory progress make it a more stable choice. Conclusion If you prefer a safer option with near-term catalysts, TNXP may be better. If you’re seeking high-risk, high-reward opportunities in oncology, ACHL could be appealing.
0 · Reply
Scanners_Free
Scanners_Free Feb. 28 at 12:07 PM
$ACHL NNEEEWS OUT
0 · Reply
ajmrtxl
ajmrtxl Feb. 18 at 4:41 PM
$ACHL's recent data from Squeezefinder
0 · Reply
PenkeTrading
PenkeTrading Feb. 5 at 11:05 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Achilles Therapeutics PLC ADR. Is that bullish or bearish? $ACHL #Achilles #RsiOverbought #NASDAQ
0 · Reply
ikkydiphoenix
ikkydiphoenix Feb. 4 at 4:07 PM
$ACHL KimAnthony are you still alive? lol
0 · Reply
Latest News on ACHL
Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

Dec 24, 2024, 9:30 AM EST - 10 months ago

Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

Nov 19, 2024, 7:00 AM EST - 1 year ago

Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

Achilles Therapeutics Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 7:00 AM EST - 1 year ago

Achilles Therapeutics Reports Third Quarter 2024 Financial Results

Achilles Therapeutics Announces Strategic Update

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Achilles Therapeutics Announces Strategic Update

Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates

Aug 14, 2024, 7:00 AM EDT - 1 year ago

Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

May 22, 2024, 7:00 AM EDT - 1 year ago

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

May 17, 2024, 5:00 PM EDT - 1 year ago

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024, 7:00 AM EDT - 1 year ago

Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

Apr 4, 2024, 6:45 AM EDT - 1 year ago

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

Apr 4, 2024, 6:30 AM EDT - 1 year ago

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference

Feb 5, 2024, 7:00 AM EST - 1 year ago

Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference

Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment' on Strategy for Improved Neoantigen Immunogenicity Prediction

Dec 18, 2023, 7:00 AM EST - 2 years ago

Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment' on Strategy for Improved Neoantigen Immunogenicity Prediction

Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

Nov 13, 2023, 4:30 PM EST - 2 years ago

Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 4, 2023, 7:00 AM EDT - 2 years ago

Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Achilles Therapeutics to Present at Upcoming Conferences

Jun 12, 2023, 8:00 AM EDT - 2 years ago

Achilles Therapeutics to Present at Upcoming Conferences

Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 10, 2023, 7:15 AM EDT - 2 years ago

Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Achilles Therapeutics' New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens

May 10, 2023, 7:00 AM EDT - 2 years ago

Achilles Therapeutics' New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens

Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status

Apr 25, 2023, 7:00 AM EDT - 2 years ago

Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status

Achilles Therapeutics to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Apr 17, 2023, 8:00 AM EDT - 2 years ago

Achilles Therapeutics to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights

Mar 7, 2023, 7:00 AM EST - 2 years ago

Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights

Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 20, 2022, 8:30 AM EST - 3 years ago

Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Achilles Therapeutics: The First Full Position In My Tax Loss Selling Basket

Dec 18, 2022, 7:14 AM EST - 3 years ago

Achilles Therapeutics: The First Full Position In My Tax Loss Selling Basket

Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022

Dec 6, 2022, 6:00 AM EST - 3 years ago

Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022

Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022

Nov 30, 2022, 6:05 PM EST - 3 years ago

Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022

Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method

Nov 22, 2022, 8:00 AM EST - 3 years ago

Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method

Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Nov 8, 2022, 7:00 AM EST - 3 years ago

Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy

Oct 6, 2022, 8:30 AM EDT - 3 years ago

Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy

Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Aug 9, 2022, 7:00 AM EDT - 3 years ago

Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing

Jul 21, 2022, 8:00 AM EDT - 3 years ago

Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing

Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board

Jun 30, 2022, 8:00 AM EDT - 3 years ago

Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board

Achilles Therapeutics Recognized with the 2022 PING Innovation Award

Jun 21, 2022, 8:30 AM EDT - 3 years ago

Achilles Therapeutics Recognized with the 2022 PING Innovation Award

Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

May 10, 2022, 7:00 AM EDT - 3 years ago

Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma

May 9, 2022, 7:00 AM EDT - 3 years ago

Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma

Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors

May 4, 2022, 8:00 AM EDT - 3 years ago

Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors

Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US

Apr 12, 2022, 7:30 AM EDT - 3 years ago

Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US

The Center for Breakthrough Medicines (CBM) Strikes Multi-Year Deal with UK Cell Therapy Powerhouse

Apr 12, 2022, 7:30 AM EDT - 3 years ago

The Center for Breakthrough Medicines (CBM) Strikes Multi-Year Deal with UK Cell Therapy Powerhouse

Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting

Apr 4, 2022, 8:00 AM EDT - 3 years ago

Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting

Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

Mar 8, 2022, 8:00 AM EST - 3 years ago

Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business Highlights

Mar 1, 2022, 7:02 AM EST - 3 years ago

Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business Highlights

Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.

Feb 7, 2022, 7:30 AM EST - 4 years ago

Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.

Achilles Therapeutics Provides Business Update and Outlook for 2022

Jan 13, 2022, 7:30 AM EST - 4 years ago

Achilles Therapeutics Provides Business Update and Outlook for 2022

Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference

Dec 21, 2021, 8:00 AM EST - 4 years ago

Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference

Achilles Therapeutics Added to the NASDAQ Biotechnology Index

Dec 20, 2021, 8:00 AM EST - 4 years ago

Achilles Therapeutics Added to the NASDAQ Biotechnology Index

Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens

Dec 9, 2021, 7:00 AM EST - 4 years ago

Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens

Achilles Therapeutics plc (ACHL) CEO Iraj Ali on SITC & Corporate Update Call (Transcript)

Nov 12, 2021, 8:36 PM EST - 4 years ago

Achilles Therapeutics plc (ACHL) CEO Iraj Ali on SITC & Corporate Update Call (Transcript)

Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating the Ability to Detect, Quantify and Track Patient-specific cNeT and Significant Increase in cNeT Dose from VELOS™ Process 2 Manufacturing

Nov 12, 2021, 7:00 AM EST - 4 years ago

Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating the Ability to Detect, Quantify and Track Patient-specific cNeT and Significant Increase in cNeT Dose from VELOS™ Process 2 Manufacturing

Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies

Nov 10, 2021, 8:15 AM EST - 4 years ago

Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies

Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

Nov 9, 2021, 8:00 AM EST - 4 years ago

Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstrating its Proprietary Manufacturing Process Can Generate Potent, Personalized Anti-Cancer Cell Therapy Candidates in Multiple Solid Tumor T

Oct 22, 2021, 7:30 AM EDT - 4 years ago

Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstrating its Proprietary Manufacturing Process Can Generate Potent, Personalized Anti-Cancer Cell Therapy Candidates in Multiple Solid Tumor T

Achilles Therapeutics to join the Northern Alliance Advanced Therapy Treatment Centre consortium

Oct 12, 2021, 8:00 AM EDT - 4 years ago

Achilles Therapeutics to join the Northern Alliance Advanced Therapy Treatment Centre consortium

DrevanTheStillblade
DrevanTheStillblade Oct. 19 at 4:23 PM
Watch VRME possible super run incoming VRME has a rare “floor + optional upside” setup. Strong cash reserves, improving cash flow, tight structure and a golden cross brewing. When volume steps in, this could stretch beyond typical penny stock ranges. $GLMD $ATHE $ACHL $CRVS
1 · Reply
AttractDontChase
AttractDontChase Sep. 28 at 6:11 PM
IVDA is the sleeper AI + drone play people will pretend they knew about later. With a tiny float and commercial-ready robotics, it could re-rate hard off any government, defense, or safety contract. Bottomed. Unloved. Loaded. $UBX $QH $SGH $ACHL $VYNE
0 · Reply
TradeHuntFish
TradeHuntFish Sep. 24 at 11:15 AM
XPON - The lithium wave is real XPON is tied directly to it. Energy storage, home power, marine, RV all real-world growth verticals. Float is small. Chart is coiled. The next PR or volume burst could launch it. $NLST $SNSE $ACHL $BTTX $GLSI
0 · Reply
rastytwits
rastytwits Mar. 27 at 4:25 PM
$ACHL now that it’s delisted from Nasdaq, how do I sell my shares? Missed the delisting notice.
1 · Reply
Laynester
Laynester Mar. 18 at 2:53 PM
$ACHL Seeing a see of green on $ACHL
0 · Reply
BuyLowSellHigh88
BuyLowSellHigh88 Mar. 14 at 5:46 PM
$ACHL Reasons to Favor TNXP 1. Broad Pipeline: TNXP has a more diversified portfolio targeting multiple conditions, which reduces reliance on a single therapy. 2. Regulatory Progress: TNXP’s lead candidate (TNX-102 SL) is closer to commercialization, with an FDA PDUFA date set for August 2025. 3. Strategic Partnerships: Strong collaborations with Bilthoven Biologicals and X-Chem, Inc. enhance its research capabilities. Key Considerations • Risk: ACHL is riskier due to its narrower focus and recent decision to discontinue key trials, signaling challenges in its pipeline. • Diversification: TNXP’s broader pipeline and advanced regulatory progress make it a more stable choice. Conclusion If you prefer a safer option with near-term catalysts, TNXP may be better. If you’re seeking high-risk, high-reward opportunities in oncology, ACHL could be appealing.
0 · Reply
Scanners_Free
Scanners_Free Feb. 28 at 12:07 PM
$ACHL NNEEEWS OUT
0 · Reply
ajmrtxl
ajmrtxl Feb. 18 at 4:41 PM
$ACHL's recent data from Squeezefinder
0 · Reply
PenkeTrading
PenkeTrading Feb. 5 at 11:05 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Achilles Therapeutics PLC ADR. Is that bullish or bearish? $ACHL #Achilles #RsiOverbought #NASDAQ
0 · Reply
ikkydiphoenix
ikkydiphoenix Feb. 4 at 4:07 PM
$ACHL KimAnthony are you still alive? lol
0 · Reply
moonwalker1231
moonwalker1231 Feb. 4 at 3:47 PM
$CPIX $ACON $EVAX $ACHL $EMPD As I said
0 · Reply
topstockalerts
topstockalerts Feb. 4 at 3:47 PM
Top Gainers PT2 $ZONE $PLTR $FLXS $ACON $ACHL Details: https://topstockalerts.com/market-gainers-and-losers/
1 · Reply
topstockalerts
topstockalerts Feb. 4 at 3:14 PM
Top Gainers PT2 $ZONE $PLTR $FLXS $ACON $ACHL Details: https://topstockalerts.com/market-gainers-and-losers/
1 · Reply
Schorsch11
Schorsch11 Feb. 4 at 2:54 PM
$ACHL They have around 2$/share to distribute. Quarterly burn approx. 20m$ (before cut of workforce) and they got 12.4m for R&D and 12m from Astra. OS approx. 41m. Good Deal and it's much better than positive trial data
0 · Reply
topstockalerts
topstockalerts Feb. 4 at 2:34 PM
Morning Movers $ACHL $AMOD $EVAX $QNTM $EMPD
0 · Reply
KimAntony
KimAntony Feb. 4 at 2:23 PM
$ACHL wait for it ... big sell imbalance ... and very quickly back down to below $1.30!
1 · Reply
Market_Max
Market_Max Feb. 4 at 2:20 PM
$TPST Steve Brady, sell this shit for $5 and go the fuck away. Follow $ACHL. Go home.
0 · Reply
Market_Max
Market_Max Feb. 4 at 2:18 PM
$CHRS I would so love for Denny to sell Tori rights right now for $1.50 per share, add to about $2.85 per share cash on hand after closing of the asset sale and disposition of any remaining debts and return cash to shareholders in a liquidation. The would be $4.35 per share for each shareholder. I ABSOLUTELY do not trust Denny & Co to achieve anything worthwhile with the cash they will be getting. I can smell it already. Look at what $ACHL just did Denny. Follow their lead and just go home!
2 · Reply
topstockalerts
topstockalerts Feb. 4 at 2:15 PM
$ACHL setting up nicely here
0 · Reply
makny
makny Feb. 4 at 2:11 PM
$ACHL it’s time to cut your losses and preserve whatever money is left. Anyone hoping for a miracle after the liquidation News is in a big surprise. Going below one dollar after open.
0 · Reply
KimAntony
KimAntony Feb. 4 at 2:08 PM
$ACHL just waiting for the huge drop now as soon as the big sell imbalance comes out at 9:25 EST.
0 · Reply